This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, F. Articles by Wada, H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, F. Articles by Wada, H.

Evaluation of Angiogenesis in Non-small Cell Lung Cancer

Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody¹

Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

Purpose: Angiogenesis is an essential process in the progression of malignant tumors. Whereas pan-endothelial markers, such as CD34, are generally used in evaluation of angiogenesis, pan-endothelial antibodies react with not only "newly forming" vessels but also normal vessels just trapped within tumor tissues. It has been recently reported that anti-CD105 antibody preferentially reacts with "activated" endothelial cells in angiogenic tissues. Thus, the superiority of anti-CD105 monoclonal antibody (mAb) in evaluation of angiogenesis of non-small cell lung cancer (NSCLC) was assessed.

Experimental Design: A total of 236 patients with resected NSCLC were retrospectively reviewed. Intratumoral microvessel density (IMVD) was determined with an anti-CD34 mAb (CD34-IMVD) and with an anti-CD105 mAb (CD105-IMVD).

Results: The mean CD34-IMVD and CD105-IMVD were 179.9 and 41.6, respectively. Whereas CD34-IMVD was significantly correlated with the expression of vascular endothelial growth factor (P = 0.003), CD105-IMVD was more closely correlated with vascular endothelial growth factor expression (P < 0.001). The 5-year survival rate of the lower CD105-IMVD patients was 74.9%, significantly higher than that of the higher CD105-IMD patients (60.4%, P = 0.018). Whereas the 5-year survival rate of the lower CD34-IMVD patients seemed higher than that of the higher CD34-IMVD patients (63.7%), the difference did not reach a statistical significance (P = 0.137). Multivariate analysis confirmed that higher CD105-IMVD was a significant factor to predict poor prognosis (P = 0.029), whereas CD34-IMVD was not (P = 0.070).

Conclusions: Anti-CD105 mAb proved to be superior to anti-CD34 mAb in evaluation of angiogenesis in NSCLC.

This article has been cited by other articles:

				R. S. Svatek, J. A. Karam, C. G. Roehrborn, P. I. Karakiewicz, K. M. Slawin, and S. F. Shariat Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy Clin. Cancer Res., June 1, 2008; 14(11): 3362 - 3366. [Abstract] [Full Text] [PDF]

				E. Ogawa, K. Takenaka, H. Katakura, M. Adachi, Y. Otake, Y. Toda, H. Kotani, T. Manabe, H. Wada, and F. Tanaka Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC) Ann. Surg. Oncol., February 1, 2008; 15(2): 547 - 554. [Abstract] [Full Text] [PDF]

				G. Bellone, D. Solerio, L. Chiusa, G. Brondino, A. Carbone, A. Prati, T. Scirelli, M. Camandona, G. Palestro, and M. Dei Poli Transforming Growth Factor-{beta} Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence Ann. Surg. Oncol., November 1, 2007; 14(11): 3232 - 3242. [Abstract] [Full Text] [PDF]

				Y. Yao, Y. Pan, J. Chen, X. Sun, Y. Qiu, and Y. Ding Endoglin (CD105) Expression in Angiogenesis of Primary Hepatocellular Carcinomas: Analysis using Tissue Microarrays and Comparisons with CD34 and VEGF Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 39 - 48. [Abstract] [Full Text] [PDF]

				X. Yao, C.-N. Qian, Z.-F. Zhang, M.-H. Tan, E. J. Kort, X. J. Yang, J. H. Resau, and B. T. Teh Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications Clin. Cancer Res., January 1, 2007; 13(1): 161 - 169. [Abstract] [Full Text] [PDF]

				M. Nakagawa, H. Katakura, M. Adachi, K. Takenaka, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka Maspin Expression and Its Clinical Significance in Non-Small Cell Lung Cancer Ann. Surg. Oncol., November 1, 2006; 13(11): 1517 - 1523. [Abstract] [Full Text] [PDF]

				A. C Lazaris, S. Tseleni-Balafouta, T. Papathomas, T. Brousalis, G. Thomopoulou, G. Agrogiannis, and E. S Patsouris Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur. J. Endocrinol., June 1, 2006; 154(6): 827 - 833. [Abstract] [Full Text] [PDF]

				O. Ozdemir The role of mast cell and mast cell subtypes (MC(T) and MC(CT)) in tumor angiogenesis. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 638 - 639. [Full Text] [PDF]

				J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al. Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas J. Nucl. Med., March 1, 2006; 47(3): 419 - 425. [Abstract] [Full Text] [PDF]

				K. Takenaka, S. Ishikawa, K. Yanagihara, R. Miyahara, S. Hasegawa, Y. Otake, Y. Morioka, C. Takahashi, M. Noda, H. Ito, et al. Prognostic Significance of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs Expression in Resected Pathologic Stage IIIA N2 Non-Small-Cell Lung Cancer Ann. Surg. Oncol., October 1, 2005; 12(10): 817 - 824. [Abstract] [Full Text] [PDF]

				K. Takenaka, E. Ogawa, H. Oyanagi, H. Wada, and F. Tanaka Carbonyl Reductase Expression and Its Clinical Significance in Non-Small-Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1972 - 1975. [Abstract] [Full Text] [PDF]

				R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]

				S. Ishikawa, T. Nakagawa, R. Miyahara, Y. Kawano, K. Takenaka, K. Yanagihara, Y. Otake, H. Katakura, H. Wada, and F. Tanaka Expression of MDA-7/IL-24 and Its Clinical Significance in Resected Non-Small Cell Lung Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1198 - 1202. [Abstract] [Full Text] [PDF]

				F. Chen, K. Takenaka, E. Ogawa, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka Flt-4-Positive Endothelial Cell Density and Its Clinical Significance in Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8548 - 8553. [Abstract] [Full Text] [PDF]

				S. Ishikawa, K. Takenaka, K. Yanagihara, R. Miyahara, Y. Kawano, Y. Otake, S. Hasegawa, H. Wada, and F. Tanaka Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non-Small-Cell Lung Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6579 - 6585. [Abstract] [Full Text] [PDF]

				F. Tanaka, K. Yanagihara, Y. Otake, Y. Kawano, R. Miyahara, K. Takenaka, H. Katakura, S. Ishikawa, H. Ito, and H. Wada Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer Ann. Surg. Oncol., June 1, 2004; 11(6): 612 - 618. [Abstract] [Full Text] [PDF]

				T C Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, and G Tonini Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer J. Clin. Pathol., June 1, 2004; 57(6): 591 - 597. [Abstract] [Full Text] [PDF]

				F. Tanaka, H. Oyanagi, K. Takenaka, S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, M. Li, Y. Otake, and H. Wada Glomeruloid Microvascular Proliferation Is Superior to Intratumoral Microvessel Density as a Prognostic Marker in Non-Small Cell Lung Cancer Cancer Res., October 15, 2003; 63(20): 6791 - 6794. [Abstract] [Full Text] [PDF]

				C. Li, R. Issa, P. Kumar, I. N. Hampson, J. M. Lopez-Novoa, C. Bernabeu, and S. Kumar CD105 prevents apoptosis in hypoxic endothelial cells J. Cell Sci., July 1, 2003; 116(13): 2677 - 2685. [Abstract] [Full Text] [PDF]

				T. Klein, Z. Ling, H. Heimberg, O. D. Madsen, R. S. Heller, and P. Serup Nestin Is Expressed in Vascular Endothelial Cells in the Adult Human Pancreas J. Histochem. Cytochem., June 1, 2003; 51(6): 697 - 706. [Abstract] [Full Text] [PDF]

				S. E. DUFF, C. LI, J. M. GARLAND, and S. KUMAR CD105 is important for angiogenesis: evidence and potential applications FASEB J, June 1, 2003; 17(9): 984 - 992. [Abstract] [Full Text] [PDF]

				F. Tanaka, S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, M. Li, Y. Otake, and H. Wada Expression of Angiopoietins and Its Clinical Significance in Non-Small Cell Lung Cancer Cancer Res., December 1, 2002; 62(23): 7124 - 7129. [Abstract] [Full Text] [PDF]

				Y.-J. Lee, N. Nagai, C.-H. Siar, K. Nakano, H. Nagatsuka, H. Tsujigiwa, C.-H. Roan, and M. Gunduz Angioarchitecture of Primary Oral Malignant Melanomas J. Histochem. Cytochem., November 1, 2002; 50(11): 1555 - 1562. [Abstract] [Full Text] [PDF]

				L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]